In line with our strategic objective to establish and strengthen our position in the formulations business both Ethical and Generics, the Company has set up a new state-of-the-art marketing office at The Great Eastern Centre, Nehru Place, New Delhi, 110019, IN.
This office will be the central hub for all operations related to our Ethical Pharmaceutical Business, encompassing critical functions such as Marketing, Business Development, HR, New Product Development, Admin, and Medical Affairs. Our goal is to create a cohesive and highly functional environment that aligns with our mission to recapture slot in India's top pharmaceutical companies.
The Delhi office is specifically designed to lead and drive marketing efforts for our Ethical Pharma Business and manage field sales force. By investing in this infrastructure and expanding our operational capabilities, we are positioning ourselves to capture a larger market share in India's burgeoning pharmaceutical sector.
At the heart of this initiative is a 14-member core team comprising of seasoned industry experts, marketing professionals, and product development specialists. This team will work on planning, executing, and managing marketing strategies that are pivotal for our business growth.
The team supporting the marketing initiative include:
1. Mr. Vivek Mishra, Vice President, Ethical Business - spearheading overall business strategy, execution, and market growth.
2. Mr. Priyanshu Tyagi, Group Product Manager - leading product management and market positioning.
3. Mr. Arvind, AGM, Medico-Marketing, Medical Affairs, Medical Training - ensuring compliance, medical communication, and training of our field force.
4. New Product Development Team - focusing on the introduction of innovative pharma solutions tailored to India's healthcare needs.
5. Learning & Development Team - responsible for continuous training and capability building of our workforce.
6. Generic Business Team under the leadership of Mr. Viren Nagar, VP-Generic Business.
Commitment to Long-Term Value Creation
At Ind Swift Laboratories Ltd, we are committed to delivering long-term value to our investors by driving consistent growth. The opening of the Marketing office at Delhi shall be a major milestone on our Journey towards achieving market leadership in the pharmaceuticals market.
Shares of Ind-Swift Laboratories Limited was last trading in BSE at Rs. 135.45 as compared to the previous close of Rs. 141.30. The total number of shares traded during the day was 16965 in over 212 trades.
The stock hit an intraday high of Rs. 143.80 and intraday low of 134.55. The net turnover during the day was Rs. 2329553.00. |
